Showing 2321-2330 of 3355 results for "".
Therapeutic Review: A Host of New Treatments Emerged in 2018
https://practicaldermatology.com/topics/psoriasis/therapeutic-review-a-host-of-new-treatments-emerged-in-2018/20381/Here's a handy reference to new drugs and devices—and other key developments—this year.DermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-38/23774/Therapeutic Advances in the Topical Management of Acne
https://practicaldermatology.com/issues/supplements/therapeutic-advances-in-the-topical-management-of-acne/21618/Rhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-rhatigan-to-merz-moc-dissatisfaction-syneron-candela-sale/18485/Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of SyMOC Sparks Anger, Frustration in Physician Community
https://practicaldermatology.com/topics/practice-management/moc-sparks-anger-frustration-in-physician-community/20898/Anti-MOC advocates wonder why they cannot get a seat at the table to discuss changing the system.Hidradenitis Suppurativa: Seeking More Pieces to the Puzzle
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-seeking-more-pieces-to-the-puzzle/23669/Evidence suggests that integrated approaches to care may yield best results for many patients.Biosimilars: Generic Biologics or Something Much More Complex?
https://practicaldermatology.com/topics/practice-management/biosimilars-generic-biologics-or-something-much-more-complex/21013/The looming availability of biosimilar medications raises important clinical and regulatory questions.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-40/23808/